News coverage about Novartis (NYSE:NVS) has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novartis earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.0797797159365 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
Novartis (NYSE NVS) traded up $0.37 during trading on Friday, reaching $84.86. The company’s stock had a trading volume of 1,280,000 shares, compared to its average volume of 1,196,021. Novartis has a 1 year low of $69.53 and a 1 year high of $86.90. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08. The company has a market capitalization of $200,744.39, a PE ratio of 17.87, a PEG ratio of 2.69 and a beta of 0.73.
Novartis (NYSE:NVS) last released its earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.25 by $0.04. Novartis had a return on equity of 15.77% and a net margin of 13.73%. The firm had revenue of $12.41 billion for the quarter, compared to analysts’ expectations of $12.21 billion. During the same quarter in the previous year, the business posted $1.23 earnings per share. The business’s revenue for the quarter was up 2.4% on a year-over-year basis. research analysts forecast that Novartis will post 4.75 earnings per share for the current year.
A number of research analysts recently commented on the company. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis in a research note on Tuesday, October 24th. Bank of America downgraded Novartis from a “neutral” rating to an “underperform” rating in a research note on Wednesday, December 6th. Leerink Swann boosted their price target on Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Finally, Zacks Investment Research downgraded Novartis from a “buy” rating to a “hold” rating in a research note on Friday, October 6th. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating and four have issued a buy rating to the stock. Novartis has an average rating of “Hold” and an average price target of $85.32.
TRADEMARK VIOLATION WARNING: This report was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/17/novartis-nvs-given-daily-coverage-optimism-score-of-0-04.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.